Company Profile
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications.
Corporate
BioXcel Therapeutics
Erik Kopp
T: 203-494-7062
Ekopp@bioxceltherapeutics.com
Investor
BioXcel Therapeutics
Brennan Doyle
T: 475-355-8462
Bdoyle@bioxceltherapeutics.com
Media
Russo Partners
David Schull
T: 858-717-2310
David.schull@russopartnersllc.com
Scott Stachowiak
T: 646-942-5630
Scott.stachowiak@russopartnersllc.com
Transfer Agent
American Stock Transfer and Trust
Auditor
Ernst & Young LLP
Legal Counsel
Latham & Watkins LLP
Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Stock Chart
Featured News
Events
SEC Filings
Filing date | Form | Description | Filing Group |
---|---|---|---|
PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
|
PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
Data Provided by Refinitiv. Minimum 15 minutes delayed.